Tandem Diabetes Care, Inc.(TNDM)Earnings, Financials & Key RatiosTandem Diabetes Care, Inc. (TNDM) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity position, highlighted by a $90.6M cash balance in 2025Q4 against persistent operational cash burn, suggests significant risk of future dilutive financing.
Tandem Diabetes Care, Inc. (TNDM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Tandem Diabetes Care, Inc. (TNDM) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.30vs $0.46+34.8% | $247Mvs $240M+2.8% |
| Q1 2026 | Feb 19, 2026 | $0.01vs $0.05+80.0% | $290Mvs $277M+4.8% |
| Q4 2025 | Nov 6, 2025 | $0.31vs $0.31+0.0% | $249Mvs $277M-10.0% |
| Q3 2025 | Aug 6, 2025 | $0.48vs $0.40-20.0% | $241Mvs $250M-3.8% |
Recent stock market news and headlines for Tandem Diabetes Care, Inc. (TNDM)
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after th
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabet.
Key metrics vs top competitors for Tandem Diabetes Care, Inc. (TNDM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.42 | $1.06B | -5.07 | 7.93% | -20.17% | -97.88% | — | |
| $159.77 | $11.22B | 45.91 | 30.73% | 10.44% | 21.38% | — | |
| $72.38 | $27.93B | 34.63 | 15.6% | 19.31% | 33.83% | — | |
| $254.76 | $450.11B | 107.49 | 8.57% | 5.79% | 67.46% | — | |
| $83.06 | $106.64B | 22.27 | 8.43% | 13.2% | 9.78% | — | |
| $49.26 | $218.9B | 14.00 | 6.43% | 37.2% | 66.36% | — |
Tandem Diabetes Care, Inc. (TNDM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Tandem Diabetes Care, Inc. (TNDM) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 7, 2026·SEC
Feb 27, 2026·SEC
Get notified when TNDM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tandem Diabetes Care, Inc. (TNDM) stock FAQ — growth, dividends, profitability & financials explained
Tandem Diabetes Care, Inc. (TNDM) reported $1.03B in revenue for fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) grew revenue by 7.9% over the past year. This is steady growth.
Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $94.5M for fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) has a return on equity (ROE) of -97.9%. Negative ROE indicates the company is unprofitable.
Tandem Diabetes Care, Inc. (TNDM) had negative free cash flow of $3.6M in fiscal year 2025, likely due to heavy capital investments.
